华夏博联为您找到"

www.am0010.com

"相关结果约1,770个
您是不是要访问: http://www.am0010.com

ARMO BioSciences Presents New Phase 1b Clinical Data for ...

Jan 20, 2017 ... REDWOOD CITY, Calif., Jan. 20, 2017 /PRNewswire/ -- ARMO BioSciences Presents New Phase 1b Clinical Data for AM0010 in Advanced ...
www.prnewswire.com/.../armo-biosciences-presents-n...

AM0010 Plus FOLFOX Shows Promise in Metastatic Pancreatic ...

Jun 29, 2017 ... Combination therapy with AM0010, a PEGylated human interleukein (IL)-10, plus fluorouracil (5-FU), leucovorin, and oxaliplatin (FOLFOX) ...
www.onclive.com/.../am0010-plus-folfox-shows-promi...

ARMO | Clinical Development

Our lead product candidate is AM0010, a long-acting form of recombinant human Interleukin 10 (IL-10). IL-10 is a naturally occurring immune growth factor in ...
www.armobio.com/clinicaldevelopment-main.php

Definition of pegylated recombinant human interleukin-10 AM0010 ...

Upon subcutaneous administration, pegylated recombinant human interleukin-10 AM0010 may activate cell-mediated immunity against cancer cells by ...
www.cancer.gov/publications/dictionaries/cancer-dr...

Study of AM0010 With FOLFOX Compared to FOLFOX Alone ...

AM0010 (5 μg/kg) dosed on Days 1-5 and Days 8-12 SQ plus FOLFOX (dl-LV 400 mg/m2 and oxaliplatin 85 mg/m2 followed by bolus 5-FU 400 mg/m2 and a ...
clinicaltrials.gov/ct2/show/NCT02923921

Combining Cytokine-based Immunotherapy AM0010 with ...

Sep 26, 2016 ... Combining Cytokine-based Immunotherapy AM0010 with Pembrolizumab Yielded Durable Responses in Patients with Advanced Solid Tumors.
www.aacr.org/Newsroom/Pages/News-Release-Detail.as...

ARMO | Presentations

PEGylated human IL‐10 (AM0010) in combination with pembrolizumab in anti‐ PD1 and CTLA‐4 refractory melanoma. Abstract #3084, ASCO 2017 Annual ...
www.armobio.com/news-presentations.php

A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors

This is a first-in-human, open-label, dose escalation study to evaluate the safety and tolerability of AM0010 in patients with advanced solid tumors, dosed daily ...
clinicaltrials.gov/ct2/show/NCT02009449

ARMO BioSciences' Immunotherapy AM0010 Receives Orphan ...

Dec 22, 2016 ... 22, 2016 /PRNewswire/ -- ARMO BioSciences' Immunotherapy AM0010 Receives Orphan Designation in Europe for the Treatment of...
www.prnewswire.com/.../armo-biosciences-immunother...